🌍·4d agoIndustry
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
Publisher
I
InflaRx
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on inflarx.de
Leave the platform to read the original full article on the publisher site.
Source: InflaRx
Scope: Industry
Related coverage
More related coverage
Mirati Therapeutics (BMS)·2d ago
Subscribe to Press release email alerts
Sign up for BMY email alerts and receive timely updates on press releases.
argenx US·2d ago
argenx announces Annual General Meeting of Shareholders on May 6, 2026
argenx US·2d ago
The latestargenx announces Annual General Meeting of Shareholders on May 6, 2026Read more
Relmada Therapeutics·2d ago
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated...